Proactive Investors - Run By Investors For Investors

Bio-Gene Technology’s Flavocide toxicology studies deliver positive results

The company is now preparing dosages for the next stage of toxicology testing.
Bio-Gene Technology’s Flavocide toxicology studies deliver positive results
Bio-Gene aims to commercialise a broad portfolio of insect control and management solutions

Bio-Gene Technology Ltd (ASX:BGT) has received positive results from its 28-day repeat-dose oral and dermal mammalian toxicology studies.

The results showed no observable adverse effects on rats from exposure to Flavocide at the doses tested and will assist in determining appropriate doses for the next stage of studies, including longer-term repeat-dose testing.

The longer-term repeat dose toxicity tests are a standard requirement for registration of insecticide products worldwide.

Flavocide is a nature-identical beta-triketone molecule patented by Bio-Gene, with flavesone as its active constituent.

Results an important de-risking milestone

Bio-Gene executive director research and development Peter May said the results represented an important de-risking milestone for ongoing commercial development.

“[The studies] will form the basis for determining the parameters of longer-term repeat-dose toxicity testing.

“[This] is an essential and important component of Flavocide’s data package in support of global registration and commercialisation of the product.”

READ: Bio-Gene Technology’s Flavocide reaffirmed as being safer on beneficial crop insects

Bio-Gene is developing the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity.

Its platform technology is based on a naturally-occurring class of chemicals known as beta-triketones.

These chemicals have demonstrated insecticidal activity – killing or knocking down insects – and may provide multiple potential new solutions for insecticide manufacturers in applications across animal health, crop protection, public health, and in consumer applications.

View full BGT profile View Profile

Bio-Gene Technology Ltd Timeline

Related Articles

The company expects to open its vault for even more cash takings
January 22 2019
Contracted revenues were $3.7 million last quarter but didn’t include Solo app sales for Samsung watches.
Bitcoin coins in a wallet
December 22 2018
The payment processing company’s platform has continued to sign up merchants, unbothered by the notorious market volatility
May 29 2019
"We aim to continue to improve the group's profitability and manage a regular and growing dividend stream for the benefit of our shareholders," said CEO Brian Raven

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use